Nephros (NEPH) Competitors

Nephros (NASDAQ:NEPH) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Is NEPH or ICAD more profitable?

Nephros has a net margin of -6.86% compared to iCAD's net margin of -17.81%. Nephros' return on equity of -11.39% beat iCAD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	-6.86%	-11.39%	-8.30%
iCAD	-17.81%	-15.65%	-12.52%

Which has stronger valuation and earnings, NEPH or ICAD?

Nephros has higher earnings, but lower revenue than iCAD. Nephros is trading at a lower price-to-earnings ratio than iCAD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$14.16M	1.44	-$1.58M	-$0.09	-21.44
iCAD	$19.61M	4.85	-$4.85M	-$0.21	-16.54

Which has more volatility and risk, NEPH or ICAD?

Nephros has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500.

Does the MarketBeat Community prefer NEPH or ICAD?

iCAD received 215 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 60.32% of users gave iCAD an outperform vote while only 43.33% of users gave Nephros an outperform vote.

Company	Underperform	Outperform
Nephros	Outperform Votes 13 43.33%	Underperform Votes 17 56.67%
iCAD	Outperform Votes 228 60.32%	Underperform Votes 150 39.68%

Do analysts rate NEPH or ICAD?

Nephros presently has a consensus target price of $5.00, suggesting a potential upside of 159.07%. Given Nephros' stronger consensus rating and higher probable upside, equities research analysts plainly believe Nephros is more favorable than iCAD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
iCAD	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media refer more to NEPH or ICAD?

In the previous week, iCAD had 3 more articles in the media than Nephros. MarketBeat recorded 8 mentions for iCAD and 5 mentions for Nephros. Nephros' average media sentiment score of 0.63 beat iCAD's score of 0.60 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iCAD	0 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in NEPH or ICAD?

41.1% of Nephros shares are owned by institutional investors. Comparatively, 24.6% of iCAD shares are owned by institutional investors. 4.1% of Nephros shares are owned by company insiders. Comparatively, 10.3% of iCAD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Nephros beats iCAD on 11 of the 18 factors compared between the two stocks.